Patents by Inventor Susanne Kammler

Susanne Kammler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11155816
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 26, 2021
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20210238601
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Application
    Filed: February 25, 2021
    Publication date: August 5, 2021
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20210147850
    Abstract: The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 20, 2021
    Inventors: Marco BERRERA, Josephine FELBER, Jean-Christophe HOFLACK, Susanne KAMMLER, Tony KAM-THONG, Brian LEONARD, Lykke PEDERSEN, Philipp TROPBERGER, Miriam TRIYATNI, Daniel Jeremy TURLEY, Angelina WALLIER, Jitao David ZHANG
  • Patent number: 10953034
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 23, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Publication number: 20200399641
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: December 30, 2019
    Publication date: December 24, 2020
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • Publication number: 20200157546
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • Publication number: 20200147123
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 23, 2019
    Publication date: May 14, 2020
    Applicant: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne KAMMLER, Anaïs LOPEZ, Henrik MUELLER, Søren OTTOSEN, Lykke PEDERSEN
  • Patent number: 10519450
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • Patent number: 10358643
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 23, 2019
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Morten Lindow, Jacob Ravn, Mark Turner
  • Publication number: 20190111073
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Publication number: 20190055564
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: May 29, 2018
    Publication date: February 21, 2019
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • Patent number: 10077443
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: September 18, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20180251764
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20180002701
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 4, 2018
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • Publication number: 20170349896
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 7, 2017
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Morten Lindow, Jacob Ravn, Mark Tumer
  • Publication number: 20160289677
    Abstract: The present invention relates to conjugates of antisense oligonucleotides (oligomers) that target the APOB gene at position 2265 to 2277.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 6, 2016
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Marie Lindholm, Mark Turner, Henrik Orum
  • Publication number: 20150368642
    Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 24, 2015
    Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW
  • Publication number: 20150291958
    Abstract: The present invention relates to conjugates of LNA antisense oligonucleotides (oligomers) that target ApoB.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 15, 2015
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum, Mark Turner, Marie Lindholm
  • Publication number: 20150275212
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 1, 2015
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • Publication number: 20140343127
    Abstract: The present invention relates to oligomer compounds (oligomers) which target nucleic acids encoding human SMN2 in a cell, leading to modulation of SMN2 mRNA splicing which favors full length SMN2 mRNA rather than the poorly functional truncated transcript, SMN2 ?7. Reduction of SMNA7 mRNA expression and/or increase in full length SMN2 mRNA expression are beneficial for the treatment of diseases or disorders associated with overexpression or undesirably high levels of aberrant forms of SMN2, particularly SMN2 ?7, such as spinal muscular atrophy (SMA).
    Type: Application
    Filed: November 8, 2012
    Publication date: November 20, 2014
    Inventor: Susanne Kammler